6632-63-9 Usage
General Description
NSC45719 is a chemical compound that has been identified as a potent and selective inhibitor of the protein kinase PDK1 (3-phosphoinositide-dependent protein kinase-1). PDK1 is known to play a critical role in cell growth, proliferation, and survival, making it an attractive target for anti-cancer therapies. Research has shown that NSC45719 effectively inhibits the activity of PDK1, leading to the suppression of tumor growth in several cancer cell lines. NSC45719 also demonstrates promising potential for the treatment of other diseases characterized by dysregulated PDK1 activity, such as diabetes and cardiovascular disorders. Furthermore, studies have indicated that NSC45719 may act through a unique mechanism, making it a valuable tool for further investigation into PDK1 signaling pathways and the development of targeted therapeutics.
Check Digit Verification of cas no
The CAS Registry Mumber 6632-63-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,6,3 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6632-63:
(6*6)+(5*6)+(4*3)+(3*2)+(2*6)+(1*3)=99
99 % 10 = 9
So 6632-63-9 is a valid CAS Registry Number.
InChI:InChI=1/C5H5ClN2OS/c1-10-5-7-3(6)2-4(9)8-5/h2H,1H3,(H,7,8,9)
6632-63-9Relevant articles and documents
HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
-
Page/Page column 173, (2022/02/22)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS
-
Page/Page column 22, (2010/11/25)
The invention relates to novel heterocyclic compounds of the formula (I) in free base form or in acid addition salt form, in which R1, R2, R3, R4 and A are as defined in the specification, to their preparation, to their use as medicaments for the treatment of certain nervous system disorders and to medicaments comprising them.
